EMERGENT BIOSOLUTIONS INC (EBS)
Sector: Health Care
2026 Annual Meeting Analysis
EMERGENT BIOSOLUTIONS INC · Meeting: April 29, 2026
Directors FOR
2
Directors AGAINST
2
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Class II Directors
Against Analysis
Ms. Dayal has served since July 2022, meaning her tenure fully overlaps with the 3-year underperformance period; EBS's stock fell 15.1% over three years while the company's own disclosed peer group gained a median of 9.4%, a gap of 24.5 percentage points that exceeds the 20-point trigger threshold for companies with negative absolute 3-year returns, and the 5-year record is even worse (-82.6pp vs peer median), so the 5-year mitigant does not apply.
Dr. Harsanyi has been a director since 2004 and Board Chairman since 2022, meaning his tenure encompasses the entire underperformance period; EBS's 3-year stock return of -15.1% trails the company's own peer group median of +9.4% by 24.5 percentage points (triggering the 20pp threshold for negative absolute TSR), and the 5-year gap of 82.6 percentage points below the peer median is severe enough that the 5-year mitigant cannot rescue the vote, making an AGAINST vote warranted for the board's most senior oversight figure.
For Analysis
Mr. Fowler was appointed to the board effective March 1, 2026, meaning he has served for fewer than 24 months and is exempt from the TSR underperformance trigger under policy; he also brings over 30 years of relevant healthcare finance experience appropriate for a company of this size and complexity.
Mr. Papa joined the board and became CEO in February 2024, meaning he has served fewer than 24 months as of the filing date and is exempt from the TSR underperformance trigger under policy; additionally, operating performance under his tenure has shown meaningful improvement (net income swung from a $190.6M loss in 2024 to $52.6M profit in 2025, and net leverage fell from 3.3x to 1.9x), which is relevant mitigating context even if the exemption alone is sufficient.
Of the four Class II director nominees, two receive AGAINST votes (Dayal, Harsanyi) due to EBS's sustained stock underperformance relative to its own disclosed peer group — a 3-year gap of 24.5 percentage points below the peer median triggers the policy threshold, and the 5-year record of -82.6pp below peers eliminates the 5-year mitigant. John Fowler Jr. is exempt as a brand-new director (appointed March 2026), and Joseph Papa is exempt as he joined in February 2024 (within the 24-month new-director window).
Say on Pay
✓ FORCEO
Joseph Papa
Total Comp
$5,321,147
Prior Support
84%%
Prior-year say-on-pay support was 84%, which is above the 70% threshold that would require a mandatory AGAINST vote for lack of response; the CEO's total compensation of $5,321,147 is reasonable for a turnaround-stage healthcare company of EBS's market cap and scope, and on average 73% of NEO target pay is variable and at-risk, satisfying the policy's pay-mix requirement. The one notable concern — the Compensation Committee's decision to pay out performance stock awards at 25% even though actual performance fell below the stated minimum threshold — represents a departure from strict pay-for-performance alignment, but the committee acknowledged this is not routine practice, and the company's 2025 operating results (net income of $52.6M vs. a $190.6M loss in 2024, net leverage down to 1.9x) provide meaningful context that the turnaround is real, supporting a FOR vote on balance.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
N/A
Audit Fees
$3,273,848
Non-Audit Fees
$37,502
Ernst & Young's non-audit fees (tax services of $37,502) represent only about 1.1% of audit fees ($3,273,848), well below the 50% threshold that would raise independence concerns; auditor tenure is not disclosed in the proxy so no tenure trigger can fire; and EY is a Big 4 firm fully appropriate for a company of EBS's size and complexity.
Overall Assessment
The 2026 EBS annual meeting presents a mixed ballot: two of four Class II director nominees (Harsanyi and Dayal) receive AGAINST votes due to EBS's sustained 3-year stock underperformance of 24.5 percentage points below the company's own peer group median, with no 5-year mitigant available given an even larger 5-year gap; the auditor ratification and say-on-pay proposals both pass their respective policy screens and receive FOR votes, with a noted but non-disqualifying concern about the compensation committee's use of discretion to pay out below-threshold performance awards.
Compensation Peer Group
18 companies disclosed in 2026 proxy filing